Carbetocin injection, a good medicine to prevent postpartum hemorrhage caused by uterine atony

With the opening of my country's two-child policy, the birth rate has increased by more than 15%. As the birth rate has increased, postpartum hemorrhage has become one of the most common and dangerous clinical complications in obstetrics and gynecology. The main reason is uterine atony, followed by caesarean section, placenta previa, macrosomia and other factors.

In my country, the age at first delivery of women of childbearing age has been delayed, the caesarean section rate has increased, and the number of macrosomia has increased. The incidence of postpartum hemorrhage has increased accordingly. More attention will be paid to the treatment and prevention of postpartum hemorrhage, especially the prevention of high-risk groups. Currently, oxytocin is used clinically for prevention or treatment. Compared with traditional oxytocin, the advantages of carbetocin are more obvious. Domestic and foreign clinical data show that carbetocin has good advantages when used in the third stage of labor (the third stage of labor refers to the period from the delivery of the fetus to the delivery of the placenta).

This drug was rated as the most valuable drug in the market in 2016 - carbetocin injection. Compared with oxytocin, although the sales volume of carbetocin injection is close to that of oxytocin injection, the retail price comparison is still hundreds of times different. Such a large gap is full of imagination space, which makes countless agents compete for it. However, the ideal is plump, and the reality is skinny. Compared with the approved indications of carbetocin and the indications of oxytocin (for induction of labor, oxytocin, postpartum and post-abortion uterine bleeding caused by weak or poor contraction of contractions; understanding of placental reserve function), there is a huge gap in the applicable population. , there is a saying that every woman who has a caesarean section may be a potential user of carbetocin. This statement should only be regarded as a good wish. At present, the risk of using it beyond the indication range in clinical practice is getting bigger and bigger. At the same time, we must also see that after the companies that entered the market first have promoted the product, subsequent imitations have also followed suit. From a clinical perspective, carbetocin, which is easier to operate and has better clinical effects, will gradually replace ordinary oxytocin as the drug of choice for preventing postpartum hemorrhage. Carbetocin will bind to the oxytocin receptor on the cytoplasmic membrane, increase the release of intracellular Ca2+ through its coupled G protein, and at the same time activate voltage-sensitive calcium channels, increase the concentration of Ca2+ in the cytoplasm, and cause uterine smooth muscle contraction to prevent postpartum uterine atony. Carbetocin is a long-acting oxytocin receptor agonist that acts similarly to oxytocin released from the posterior pituitary gland, with a rapid onset of action and a long duration of action. In Chengdu Chengdu Shengnuo Biotechnology Co., Ltd., the pharmaceutical company's carbetocin original drug and carbetocin injection, which are the first in China to have independent intellectual property rights, have been approved for marketing.

The company also carries out GMP certification for carbetocin raw materials, and concentrates its efforts on bidding and marketing to promote the development of the carbetocin market and achieve the revenue target within the year. At the same time, the launch of the drug has enriched the company's core product categories and optimized the company's product structure, which will have a significant positive impact on the company's performance improvement. The most important thing is to improve product quality and quality value.